474
Participants
Start Date
March 31, 2025
Primary Completion Date
May 31, 2031
Study Completion Date
May 31, 2031
Adebrelimab + paclitaxel/nab-paclitaxel + cisplatin followed by chemoradiotherapy
"Neoadjuvant treatment:~adebrelimab 1200 mg/m2 d1+ paclitaxel d1/nab-paclitaxel d1,8, + cisplatin d1, Q2W×2 followed by chemoradiotherapy (paclitaxel /nab-paclitaxel + cisplatin + 41.4Gy/23f), surgical resection 4-8 weeks later neoadjuvant treatment."
chemoradiotherapy followed by adebrelimab + paclitaxel/nab-paclitaxel + cisplatin
"Neoadjuvant treatment:~chemoradiotherapy (paclitaxel /nab-paclitaxel + cisplatin + 41.4Gy/23f), followed by adebrelimab 1200 mg/m2 d1+ paclitaxel d1/nab-paclitaxel d1,8, + cisplatin d1, Q2W×2 surgical resection 4-8 weeks later neoadjuvant treatment."
TNT treatment [TNT group one (phase 2) or TNT group two (phase 2)]
"Neoadjuvant treatment:~TNT treatment \[TNT group one (phase 2) or TNT group two (phase 2)\] followed by surgical resection 4-8 weeks later adjuvant treatment: adebrelimab 1200 mg/m2 d1, W3Q, adjuvant treatment for one year"
Chemoradiotherapy
"Neoadjuvant treatment:~chemoradiotherapy (paclitaxel 50 mg/m2/nab-paclitaxel 60 mg/m2 d1, 8, 15, 22,29 + cisplatin 25 mg/m2 d1, 8, 15, 22,29 + 41.4Gy/23f), followed by surgical resection 4-8 weeks later. adjuvant treatment: non-pCR: adebrelimab 1200 mg/m2 d1, W3Q, adjuvant treatment for one year pCR: observation"
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing
YIN LI
OTHER